CA2878991C - Glucagon analogues - Google Patents

Glucagon analogues Download PDF

Info

Publication number
CA2878991C
CA2878991C CA2878991A CA2878991A CA2878991C CA 2878991 C CA2878991 C CA 2878991C CA 2878991 A CA2878991 A CA 2878991A CA 2878991 A CA2878991 A CA 2878991A CA 2878991 C CA2878991 C CA 2878991C
Authority
CA
Canada
Prior art keywords
aib
pharmaceutically acceptable
solvate
acceptable salt
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2878991A
Other languages
English (en)
French (fr)
Other versions
CA2878991A1 (en
Inventor
Ditte Riber
Lise GIEHM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zealand Pharma AS
Original Assignee
Zealand Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma AS filed Critical Zealand Pharma AS
Publication of CA2878991A1 publication Critical patent/CA2878991A1/en
Application granted granted Critical
Publication of CA2878991C publication Critical patent/CA2878991C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CA2878991A 2012-07-23 2013-07-23 Glucagon analogues Active CA2878991C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261674706P 2012-07-23 2012-07-23
US61/674,706 2012-07-23
US201361785611P 2013-03-14 2013-03-14
US61/785,611 2013-03-14
DKPA201300360 2013-06-14
DKPA201300360 2013-06-14
PCT/EP2013/065519 WO2014016300A1 (en) 2012-07-23 2013-07-23 Glucagon analogues

Publications (2)

Publication Number Publication Date
CA2878991A1 CA2878991A1 (en) 2014-01-30
CA2878991C true CA2878991C (en) 2021-12-07

Family

ID=49996630

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2878991A Active CA2878991C (en) 2012-07-23 2013-07-23 Glucagon analogues

Country Status (27)

Country Link
US (3) US10442847B2 (OSRAM)
EP (1) EP2875043B1 (OSRAM)
JP (3) JP6534927B2 (OSRAM)
KR (1) KR102129235B1 (OSRAM)
CN (2) CN109456400A (OSRAM)
AR (1) AR091866A1 (OSRAM)
AU (1) AU2013295035B2 (OSRAM)
BR (1) BR112015001451B1 (OSRAM)
CA (1) CA2878991C (OSRAM)
DK (1) DK2875043T3 (OSRAM)
EA (1) EA033399B1 (OSRAM)
ES (1) ES2620111T3 (OSRAM)
FI (1) FIC20240034I1 (OSRAM)
FR (1) FR24C1043I2 (OSRAM)
IL (1) IL236554B (OSRAM)
IN (1) IN2015DN00544A (OSRAM)
MX (1) MX356957B (OSRAM)
MY (1) MY170671A (OSRAM)
NL (1) NL301294I2 (OSRAM)
NZ (1) NZ704043A (OSRAM)
PH (1) PH12015500115B1 (OSRAM)
PL (1) PL2875043T3 (OSRAM)
SG (1) SG11201500375PA (OSRAM)
TW (1) TWI642682B (OSRAM)
UA (1) UA117103C2 (OSRAM)
WO (1) WO2014016300A1 (OSRAM)
ZA (1) ZA201702364B (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20146056B (en) 2009-07-13 2014-03-10 Zealand Pharma As Acylated glucagon analogues
HK1208232A1 (en) 2012-05-03 2016-02-26 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
IN2015DN00544A (OSRAM) * 2012-07-23 2015-06-26 Zealand Pharma As
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG11201503524PA (en) 2012-12-21 2015-06-29 Sanofi Sa Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
PT3057984T (pt) 2013-10-17 2018-10-24 Boehringer Ingelheim Int Análogos de glucagon acilados
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
KR102310392B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
JP6682432B2 (ja) 2013-11-06 2020-04-15 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
JP6898231B6 (ja) 2014-10-29 2021-07-28 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐアゴニスト化合物及び方法
DK3283507T3 (da) 2015-04-16 2020-01-02 Zealand Pharma As Acyleret glucagonanalog
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
CN118526577A (zh) 2017-06-16 2024-08-23 西兰制药公司 用于施用胰高血糖素样肽2（glp-2）类似物的剂量方案
GB201710822D0 (en) * 2017-07-05 2017-08-16 Zealand Pharma As Methods and medical uses relating to the treatment of hypoglycaemia
MX2020000514A (es) 2017-07-14 2020-08-03 Xeris Pharmaceuticals Inc Metodos para tratar el hiperinsulinismo congenito.
AU2019211352A1 (en) * 2018-01-23 2020-07-30 Joslin Diabetes Center, Inc. Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon
WO2021185821A1 (en) * 2020-03-16 2021-09-23 Zealand Pharma A/S Liquid formulations of glucagon analogues
TW202241491A (zh) * 2020-12-16 2022-11-01 丹麥商西蘭製藥公司 Ｇｌｐ－１／ｇｌｐ－２雙重促效劑之醫藥組合物
MX2023015068A (es) * 2021-06-18 2024-01-17 Beijing Tuo Jie Biopharmaceutical Co Ltd Analogo de glucagon y uso medico del mismo.
CN113501871B (zh) * 2021-07-21 2022-10-28 汉肽生物医药集团有限公司 一种固液相结合制备达西高血糖素的方法
WO2025056677A1 (en) 2023-09-15 2025-03-20 Zealand Pharma A/S Dasiglucagon for use in the treatment of congenital hyperinsulinism
WO2025189109A1 (en) * 2024-03-08 2025-09-12 The Trustees Of Indiana University Glucagon analogues compatible with prandial insulin co-infusion

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4288627A (en) 1980-02-12 1981-09-08 Phillips Petroleum Company Oxidation of thiols employing cobalt molybdate/triethylamine catalyst
NZ202757A (en) 1981-12-23 1985-11-08 Novo Industri As Peptides and medicaments
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
ES2113879T3 (es) 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.
WO1991017243A1 (en) 1990-05-09 1991-11-14 Novo Nordisk A/S A cellulase preparation comprising an endoglucanase enzyme
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5846747A (en) 1992-03-25 1998-12-08 Novo Nordisk A/S Method for detecting glucagon-like peptide-1 antagonists and agonists
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
AU7531094A (en) 1993-08-24 1995-03-21 Novo Nordisk A/S Protracted glp-1
JP3821839B2 (ja) 1993-09-07 2006-09-13 アミリン・ファーマシューティカルズ，インコーポレイテッド 胃腸の運動性を調節する方法
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5523449A (en) 1995-05-17 1996-06-04 Bayer Corporation Process for preparing phosphorodichlorido-dithioates by reacting alkylmercaptans with phosphorus trichloride in the presence of sulfur
CN1183158C (zh) 1996-06-05 2005-01-05 罗赫诊断器材股份有限公司 Exendin类似物,其制备方法及含有它们的药物制剂
US6110703A (en) 1996-07-05 2000-08-29 Novo Nordisk A/S Method for the production of polypeptides
WO1998005351A1 (en) 1996-08-08 1998-02-12 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US6384016B1 (en) 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
PL192359B1 (pl) 1996-08-30 2006-10-31 Novo Nordisk As Pochodna GLP-1(7-37) lub analogu GLP-1(7-37), środek farmaceutyczny oraz zastosowanie pochodnej GLP-1(7-37) lub analogu GLP-1(7-37)
IL128828A0 (en) 1996-09-09 2000-01-31 Zealand Pharmaceuticals As Peptide prodrugs containing an alpha-hydroxy acid linker
ES2239364T3 (es) 1996-09-09 2005-09-16 Zealand Pharma A/S Sintesis de peptidos en fase solida.
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
AU5065198A (en) 1996-11-15 1998-06-10 Maria Grazia Masucci Fusion proteins having increased half-lives
ATE304864T1 (de) 1997-01-07 2005-10-15 Amylin Pharmaceuticals Inc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
US6136784A (en) 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
JP2001512307A (ja) 1997-02-05 2001-08-21 １１４９３３６ オンタリオ インコーポレーテッド プロエキセンジンをコードするポリヌクレオチドならびにその作製方法および使用
US5846937A (en) 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
EP1034163A1 (en) 1997-05-07 2000-09-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin New cysteine derivatives, processes for their production, and pharmaceuticals containing them
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
AU749914B2 (en) 1997-08-08 2002-07-04 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
ATE381939T1 (de) 1997-11-14 2008-01-15 Amylin Pharmaceuticals Inc Neuartige exendin agonisten
WO1999025728A1 (en) 1997-11-14 1999-05-27 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US7220721B1 (en) 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
CA2312190A1 (en) 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
CA2320371C (en) 1998-02-13 2012-01-17 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
WO1999043707A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
NZ506839A (en) 1998-03-09 2003-05-30 Zealand Pharma As Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
WO1999049788A1 (en) 1998-03-30 1999-10-07 Focus Surgery, Inc. Ablation system
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
JP4624558B2 (ja) 1998-08-10 2011-02-02 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ＧＬＰ−１またはＥｘｅｎｄｉｎ−４による、非インスリン産生細胞のインスリン産生細胞への分化、およびその使用
JP2002526554A (ja) 1998-10-07 2002-08-20 メディカル カレッジ オブ ジョージア リサーチ インスティチュート，インコーポレイテッド 骨親和性ホルモンとして用いられるグルコース依存性インスリン親和性ペプチド
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
CZ295891B6 (cs) 1998-12-07 2005-11-16 Societe De Conseils De Recherches Et D'application Analogy GLP-1, substituované na pozici 35, jejich použití a farmaceutické prostředky je obsahující
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
KR20020001719A (ko) 1999-01-14 2002-01-09 마크 엠. 폴렛타 글루카곤 억제 방법
NZ512663A (en) 1999-01-14 2004-05-28 Amylin Pharmaceuticals Inc Novel exendin agonist formulations and methods of administration thereof
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
CN1344248A (zh) 1999-03-17 2002-04-10 诺沃挪第克公司 肽的酰化方法和新酰化剂
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
BR0010705A (pt) 1999-04-30 2002-02-05 Amylin Pharmaceuticals Inc Exendinas modificadas e agonistas da exendina
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
EP1180121B9 (en) 1999-05-17 2004-09-08 Conjuchem, Inc. Long lasting insulinotropic peptides
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6344180B1 (en) 1999-06-15 2002-02-05 Bionebraska, Inc. GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
NZ519752A (en) 2000-10-20 2005-04-29 Amylin Pharmaceuticals Inc Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2003053460A1 (en) 2001-12-19 2003-07-03 Eli Lilly And Company Crystalline compositions for controlling blood glucose
CZ2004710A3 (cs) 2001-12-20 2005-02-16 Eli Lilly And Company Inzulínová sloučenina s protrahovaným účinkem
AU2003243929B2 (en) 2002-07-04 2009-06-04 Zp Holding Spv K/S GLP-1 and methods for treating diabetes
EP1546200A2 (en) 2002-10-02 2005-06-29 Zealand Pharma A/S Stabilized exendin-4 compounds
US7192922B2 (en) 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
KR20050121748A (ko) 2003-04-29 2005-12-27 일라이 릴리 앤드 캄파니 연장된 시간 작용을 갖는 인슐린 유사체
KR101293507B1 (ko) * 2003-06-03 2013-08-06 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
US7623530B2 (en) 2003-11-20 2009-11-24 Nokia Corporation Indication of service flow termination by network control to policy decision function
BRPI0507189A (pt) 2004-01-30 2007-06-26 Waratah Pharmaceuticals Inc uso combinado de um agonista de glp-1 e compostos de gastrina
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
MX2007005521A (es) 2004-11-12 2007-05-18 Novo Nordisk As Formulaciones estables de peptidos insulinotropicos.
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
WO2006121860A2 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
WO2006134340A2 (en) 2005-06-13 2006-12-21 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
WO2007024899A2 (en) 2005-08-23 2007-03-01 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
CA2628241C (en) * 2005-11-07 2016-02-02 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
US8343914B2 (en) 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
WO2007095737A1 (en) 2006-02-21 2007-08-30 Waratah Pharmaceuticals Inc. Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound
AU2007221366B2 (en) 2006-02-22 2012-08-23 Msd Italia S.R.L. Oxyntomodulin derivatives
MX2009000709A (es) 2006-07-18 2009-02-04 Sanofi Aventis Anticuerpo antagonista contra epha2 para el tratamiento de cancer.
ITMI20061607A1 (it) 2006-08-09 2008-02-10 Maria Vincenza Carriero Peptidi con attivita farmacologica
WO2008043033A2 (en) 2006-10-04 2008-04-10 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
US8642727B2 (en) 2006-11-08 2014-02-04 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
WO2008071010A1 (en) 2006-12-12 2008-06-19 Waratah Pharmaceuticals Inc. Combination treatments with selected growth/hormone regulatory factors for diabetes and related diseases
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
AU2008205229B2 (en) 2007-01-05 2014-03-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
EP2487184A1 (en) 2007-02-15 2012-08-15 Indiana University Research and Technology Corporation Glucagon/GLP-1 receptor co-agonists
FR2917552B1 (fr) 2007-06-15 2009-08-28 Sagem Defense Securite Procede de regulation de la gigue de transmission au sein d'un terminal de reception
JP5385266B2 (ja) 2007-06-15 2014-01-08 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
EP2025684A1 (en) 2007-08-15 2009-02-18 Zealand Pharma A/S Glucagon analogues
MX2010005317A (es) 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
GB2455553B (en) 2007-12-14 2012-10-24 Nuaire Ltd Motor mounting assembly for an axial fan
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
CA2711752A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
KR20100111682A (ko) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
WO2009129250A2 (en) 2008-04-14 2009-10-22 Case Western Reserve University Meal-time insulin analogues of enhanced stability
RU2010147076A (ru) 2008-04-22 2012-05-27 Кейз Вестерн Ризев Юнивесити (Us) Аналоги инсулина специфичные к изоформам
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
CA2729296A1 (en) 2008-06-17 2010-01-28 Richard D. Dimarchi Gip-based mixed agonists for treatment of metabolic disorders and obesity
AU2009260302B2 (en) 2008-06-17 2014-10-23 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
AU2009260301B2 (en) * 2008-06-17 2015-09-03 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
PL219335B1 (pl) 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
BRPI0916560A2 (pt) 2008-07-31 2015-11-10 Univ Case Western Reserve análogo de insulina, ácido nucléico, vetor de expressão, célula hospedeira e método de tratamento de um paciente.
BRPI0916890A2 (pt) 2008-08-07 2019-09-24 Ipsen Pharma Sas composto, composição farmacêutica, métodos para elicitar um efeito agonista, e um efeito antagonista de um receptor de gip, para tratar condições ou doeças, para tratar distúrbios, para tratar ou prevenir causas secundárias de diabete, e para estimular secreção de insulina em um indivíduo, e, uso de um composto
US8637647B2 (en) 2008-09-12 2014-01-28 Novo Nordisk A/S Method of acylating a peptide or protein
DK2370461T3 (da) 2008-12-15 2013-12-16 Zealand Pharma As Glucagonanaloger
KR20110126589A (ko) 2008-12-15 2011-11-23 질랜드 파마 에이/에스 글루카곤 유사체
KR20110126592A (ko) * 2008-12-15 2011-11-23 질랜드 파마 에이/에스 글루카곤 유사체
EA020596B1 (ru) * 2008-12-15 2014-12-30 Зилэнд Фарма А/С Аналоги глюкагона
CN102256992B (zh) 2008-12-19 2015-04-22 印第安纳大学研究及科技有限公司 胰岛素类似物
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
WO2010107487A2 (en) 2009-03-18 2010-09-23 Wu Nian Lipid-drug conjugates for drug delivery
CN101519446A (zh) 2009-03-31 2009-09-02 上海一就生物医药有限公司 一种重组人胰岛素及其类似物的制备方法
MX2011010570A (es) 2009-05-08 2011-10-19 Genentech Inc Anticuerpos anti-egfl7 humanizados y metodos de uso de los mismos.
CN102459325B (zh) 2009-06-16 2015-03-25 印第安纳大学科技研究有限公司 胃抑胜肽受体活化的胰高血糖素化合物
GEP20146056B (en) 2009-07-13 2014-03-10 Zealand Pharma As Acylated glucagon analogues
EP2513141B1 (en) 2009-12-16 2017-03-01 Novo Nordisk A/S Glp-1 analogues and derivatives
US20110312881A1 (en) 2009-12-21 2011-12-22 Amunix, Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
KR20120128129A (ko) 2010-01-20 2012-11-26 질랜드 파마 에이/에스 심장 병태의 치료
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
WO2011117417A1 (en) * 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
KR20130018410A (ko) 2010-03-26 2013-02-21 노보 노르디스크 에이/에스 새로운 글루카곤 유사체
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
WO2011134284A1 (zh) 2010-04-27 2011-11-03 浙江贝达药业有限公司 胰高血糖素样肽-1类似物及其应用
CN103003300B (zh) 2010-04-27 2017-06-09 西兰制药公司 Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
CN103068841A (zh) 2010-06-24 2013-04-24 西兰制药公司 胰高血糖素类似物
WO2011163473A1 (en) * 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
EP2637698B1 (en) 2010-11-09 2022-04-20 Novo Nordisk A/S Double-acylated glp-1 derivatives
US20140011733A1 (en) 2011-01-20 2014-01-09 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
EP2691108A1 (en) 2011-03-28 2014-02-05 Novo Nordisk A/S Novel glucagon analogues
HUE031405T2 (en) 2011-04-12 2017-07-28 Novo Nordisk As Double-acylated GLP-1 derivatives
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
WO2012153196A2 (en) 2011-05-10 2012-11-15 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
JP5914641B2 (ja) 2011-06-10 2016-05-11 ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． グルコース依存性インスリン分泌刺激ポリペプチドのアナログ、医薬組成物及びその使用
WO2013041678A1 (en) 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues
AP2014007797A0 (en) 2011-12-23 2014-07-31 Boehringer Ingelheim Int Glucagon analogues
WO2013098408A1 (en) * 2011-12-30 2013-07-04 Zealand Pharma A/S Glucagon and cck receptor agonist peptide conjugates
HK1208232A1 (en) 2012-05-03 2016-02-26 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
CA2872315A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
IN2015DN00544A (OSRAM) 2012-07-23 2015-06-26 Zealand Pharma As
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
PT3057984T (pt) 2013-10-17 2018-10-24 Boehringer Ingelheim Int Análogos de glucagon acilados
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
JP6682432B2 (ja) 2013-11-06 2020-04-15 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
RU2016134425A (ru) 2014-02-18 2018-03-20 Ново Нордиск А/С Стабильные аналоги глюкагона и их применение для лечения гипогликемии
DK3283507T3 (da) 2015-04-16 2020-01-02 Zealand Pharma As Acyleret glucagonanalog

Also Published As

Publication number Publication date
CA2878991A1 (en) 2014-01-30
MY170671A (en) 2019-08-26
DK2875043T3 (en) 2017-03-27
EP2875043B1 (en) 2016-12-21
AU2013295035B2 (en) 2017-08-03
JP2015524419A (ja) 2015-08-24
TWI642682B (zh) 2018-12-01
US11795204B2 (en) 2023-10-24
PH12015500115A1 (en) 2015-03-30
US20200207825A1 (en) 2020-07-02
FIC20240034I1 (fi) 2024-10-23
IL236554B (en) 2020-04-30
BR112015001451B1 (pt) 2022-03-29
EA033399B1 (ru) 2019-10-31
FR24C1043I2 (fr) 2025-10-10
ZA201702364B (en) 2019-05-29
PH12015500115B1 (en) 2015-03-30
CN109456400A (zh) 2019-03-12
TW201404785A (zh) 2014-02-01
IL236554A0 (en) 2015-02-26
EA201590058A1 (ru) 2015-09-30
HK1210787A1 (en) 2016-05-06
PL2875043T3 (pl) 2017-06-30
JP2019187419A (ja) 2019-10-31
SG11201500375PA (en) 2015-02-27
NZ704043A (en) 2017-07-28
WO2014016300A1 (en) 2014-01-30
US20240067696A1 (en) 2024-02-29
BR112015001451A2 (pt) 2017-07-04
KR102129235B1 (ko) 2020-07-06
US20150210744A1 (en) 2015-07-30
ES2620111T3 (es) 2017-06-27
CN104662038B (zh) 2018-11-06
MX2015000990A (es) 2015-03-20
IN2015DN00544A (OSRAM) 2015-06-26
CN104662038A (zh) 2015-05-27
AR091866A1 (es) 2015-03-04
UA117103C2 (uk) 2018-06-25
JP6534927B2 (ja) 2019-06-26
MX356957B (es) 2018-06-20
NL301294I2 (nl) 2024-11-18
JP2022023029A (ja) 2022-02-07
EP2875043A1 (en) 2015-05-27
FR24C1043I1 (fr) 2024-12-06
AU2013295035A1 (en) 2015-02-12
US10442847B2 (en) 2019-10-15
KR20150032912A (ko) 2015-03-30

Similar Documents

Publication Publication Date Title
US20240067696A1 (en) Glucagon analogues
AU2011206979B2 (en) Treatment of cardiac conditions
JP6585197B2 (ja) グルカゴン及びｇｌｐ−１共アゴニスト化合物
RU2559320C2 (ru) Новые аналоги глюкагона
US20130053310A1 (en) Novel glucagon analogues
AU2008365557A1 (en) Glucagon analogues
AU2008365559A1 (en) Glucagon analogues
TW201427993A (zh) 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
TW201733613A (zh) 用於治療肥胖之升糖素及glp-1共促效劑
TW201917134A (zh) 新穎的醯基化胰島素類似物及其用途
JP6995284B2 (ja) 新規インスリン類似体およびそれらの使用
CN102076353A (zh) 胰岛淀粉样多肽和鲑鱼降钙素的衍生杂合肽
KR20200080331A (ko) 글루카곤 유사체
HK1210787B (en) Glucagon analogues
WO2024245233A1 (zh) 一种口服递送的多肽衍生物
WO2025162423A1 (zh) 针对glp-1r、gipr和gcgr的三激动剂

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180710